Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma

1.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492..CrossRefPubMed

2.

El Kassas M, Tawheed A, Eltabbakh M, Kaseb A. Hepatitis C antiviral therapy in patients with successfully treated hepatocellular carcinoma: dancing with wolves. J Hepatocell Carcinoma. 2019;6:183–91. https://doi.org/10.2147/JHC.S206668.CrossRefPubMedPubMedCentral

3.

Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma. 2019;6:11–21. https://doi.org/10.2147/JHC.S159805.CrossRefPubMed

4.

Duan J, Wu Y, Liu J, Zhang J, Fu Z, Feng T, Liu M, Han J, Li Z, Chen S. Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine. J Hepatocell Carcinoma. 2019;6:151–66. https://doi.org/10.2147/JHC.S224849.CrossRefPubMedPubMedCentral

5.

Lee M, Ko H, Yun M. Cancer metabolism as a mechanism of treatment resistance and potential therapeutic target in hepatocellular carcinoma. Yonsei Med J. 2018;59:1143–9. https://doi.org/10.3349/ymj.2018.59.10.1143.CrossRefPubMedPubMedCentral

6.

Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745–61. https://doi.org/10.1053/j.gastro.2016.11.048.CrossRefPubMed

7.

Connell LC, Harding JJ, Abou-Alfa GK. Advanced hepatocellular Cancer: the current state of future research. Curr Treat Options in Oncol. 2016;17:43. https://doi.org/10.1007/s11864-016-0415-3.CrossRef

8.

Azim HA, Omar A, Atef H, Zawahry H, Shaker MK, Abdelmaksoud AK, EzzElarab M, Abdel-Rahman O, Ismail M, Kassem L, Waked I. Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a phase II trial (ESLC01 study). J Hepatocell Carcinoma. 2018;5:109–19. https://doi.org/10.2147/JHC.S169285.CrossRefPubMedPubMedCentral

9.

Mendez-Blanco C, Fondevila F, Garcia-Palomo A, Gonzalez-Gallego J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50:134. https://doi.org/10.1038/s12276-018-0159-1.CrossRefPubMedCentral

10.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. https://doi.org/10.1056/NEJMoa0708857.CrossRefPubMed

11.

Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG. New insights into sorafenib resistance in hepatocellular carcinoma: responsible mechanisms and promising strategies. Biochim Biophys Acta Rev Cancer. 1868;2017:564–70. https://doi.org/10.1016/j.bbcan.2017.10.002.CrossRef

12.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

13.

Schwartz L, Supuran CT, Alfarouk KO. The Warburg effect and the hallmarks of Cancer. Anti Cancer Agents Med Chem. 2017;17:164–70. https://doi.org/10.2174/1871520616666161031143301.CrossRef

14.

Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325–37. https://doi.org/10.1038/nrc3038.CrossRefPubMed

15.

Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg effect" and a pivotal target for effective therapy. Semin Cancer Biol. 2009;19:17–24. https://doi.org/10.1016/j.semcancer.2008.11.006.CrossRefPubMed

16.

Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019;95:912–9. https://doi.org/10.1080/09553002.2019.1589653.CrossRefPubMed

17.

Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003;63:3847–54.PubMed

18.

Bhattacharya B, Mohd Omar MF, Soong R. The Warburg effect and drug resistance. Br J Pharmacol. 2016;173:970–9. https://doi.org/10.1111/bph.13422.CrossRefPubMedPubMedCentral

19.

Bannasch P, Ribback S, Su Q, Mayer D. Clear cell hepatocellular carcinoma: origin, metabolic traits and fate of glycogenotic clear and ground glass cells. Hepatobiliary Pancreat Dis Int. 2017;16:570–94. https://doi.org/10.1016/S1499-3872(17)60071-7.CrossRefPubMed

20.

Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo G, Bicciato S, Dupont S. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 2015;34:1349–70. https://doi.org/10.15252/embj.201490379.CrossRefPubMedPubMedCentral

21.

Shuch B, Linehan WM, Srinivasan R. Aerobic glycolysis: a novel target in kidney cancer. Expert Rev Anticancer Ther. 2013;13:711–9. https://doi.org/10.1586/era.13.57.CrossRefPubMedPubMedCentral

22.

Xiang J, Hu Q, Qin Y, Ji S, Xu W, Liu W, Shi S, Liang C, Liu J, Meng Q, Liang D, Ni Q, Xu J, et al. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1alpha axis and indicates prognosis in pancreatic cancer. Cell Death Dis. 2018;9:321. https://doi.org/10.1038/s41419-018-0367-6.CrossRefPubMedPubMedCentral

23.

Feinberg T, Herbig J, Kohl I, Las G, Cancilla JC, Torrecilla JS, Ilouze M, Haick H, Peled N. Cancer metabolism: the volatile signature of glycolysis-in vitro model in lung cancer cells. J Breath Res. 2017;11:016008. https://doi.org/10.1088/1752-7163/aa51d6.CrossRefPubMed

24.

Yuan LW, Yamashita H, Seto Y. Glucose metabolism in gastric cancer: the cutting-edge. World J Gastroenterol. 2016;22:2046–59. https://doi.org/10.3748/wjg.v22.i6.2046.CrossRefPubMedPubMedCentral

25.

Ciccarese C, Santoni M, Massari F, Modena A, Piva F, Conti A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Tortora G, Montironi R. Metabolic alterations in renal and prostate Cancer. Curr Drug Metab. 2016;17:150–5. https://doi.org/10.2174/1389200216666151015112356.CrossRefPubMed

26.

Li S, Li J, Dai W, Zhang Q, Feng J, Wu L, Liu T, Yu Q, Xu S, Wang W, Lu X, Chen K, Xia Y, et al. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death. Br J Cancer. 2017;117:1518–28. https://doi.org/10.1038/bjc.2017.323.CrossRefPubMedPubMedCentral

27.

Beyoglu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, Idle JR. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology. 2013;58:229–38. https://doi.org/10.1002/hep.26350.CrossRefPubMed

28.

Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A. 1977;74:3735–9. https://doi.org/10.1073/pnas.74.9.3735.CrossRefPubMedPubMedCentral

29.

Gwangwa MV, Joubert AM, Visagie MH. Crosstalk between the Warburg effect, redox regulation and autophagy induction in tumourigenesis. Cell Mol Biol Lett. 2018;23:20. https://doi.org/10.1186/s11658-018-0088-y.CrossRefPubMedPubMedCentral

30.

Yin PH, Wu CC, Lin JC, Chi CW, Wei YH, Lee HC. Somatic mutations of mitochondrial genome in hepatocellular carcinoma. Mitochondrion. 2010;10:174–82. https://doi.org/10.1016/j.mito.2009.12.147.CrossRefPubMed

31.

Hsu CC, Lee HC, Wei YH. Mitochondrial DNA alterations and mitochondrial dysfunction in the progression of hepatocellular carcinoma. World J Gastroenterol. 2013;19:8880–6. https://doi.org/10.3748/wjg.v19.i47.8880.CrossRefPubMedPubMedCentral

32.

Li Y, Lin S, Li L, Tang Z, Hu Y, Ban X, Zeng T, Zhou Y, Zhu Y, Gao S, Deng W, Zhang X, Xie D, et al. PDSS2 deficiency induces Hepatocarcinogenesis by decreasing mitochondrial respiration and reprogramming glucose metabolism. Cancer Res. 2018;78:4471–81. https://doi.org/10.1158/0008-5472.CAN-17-2172.CrossRefPubMed

33.

Bai J, Liu Z, Liu J, Zhang S, Tian Y, Zhang Y, Ren L, Kong D. Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib. Aging. 2019;11:12452–75. https://doi.org/10.18632/aging.102582.CrossRefPubMedPubMedCentral

34.

Cheng G, Zielonka J, Dranka BP, McAllister D, Mackinnon AC Jr, Joseph J, Kalyanaraman B. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 2012;72:2634–44. https://doi.org/10.1158/0008-5472.CAN-11-3928.CrossRefPubMedPubMedCentral

35.

Shang RZ, Qu SB, Wang DS. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects. World J Gastroenterol. 2016;22:9933–43. https://doi.org/10.3748/wjg.v22.i45.9933.CrossRefPubMedPubMedCentral

36.

Ganapathy-Kanniappan S. Linking tumor glycolysis and immune evasion in cancer: emerging concepts and therapeutic opportunities. Biochim Biophys Acta Rev Cancer. 1868;2017:212–20. https://doi.org/10.1016/j.bbcan.2017.04.002.CrossRef

37.

Yang DQ, Freund DM, Harris BR, Wang D, Cleary MP, Hegeman AD. Measuring relative utilization of aerobic glycolysis in breast cancer cells by positional isotopic discrimination. FEBS Lett. 2016;590:3179–87. https://doi.org/10.1002/1873-3468.12360.CrossRefPubMedPubMedCentral

38.

Lis P, Dylag M, Niedzwiecka K, Ko YH, Pedersen PL, Goffeau A, Ulaszewski S. The HK2 dependent “Warburg effect” and mitochondrial oxidative phosphorylation in Cancer: targets for effective therapy with 3-Bromopyruvate. Molecules. 2016;21. https://doi.org/10.3390/molecules21121730.

39.

DeWaal D, Nogueira V, Terry AR, Patra KC, Jeon SM, Guzman G, Au J, Long CP, Antoniewicz MR, Hay N. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun. 2018;9:446. https://doi.org/10.1038/s41467-017-02733-4.CrossRefPubMedPubMedCentral

40.

Gong L, Cui Z, Chen P, Han H, Peng J, Leng X. Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II. Med Oncol. 2012;29:909–14. https://doi.org/10.1007/s12032-011-9841-z.CrossRefPubMed

41.

Xu S, Herschman HR. A tumor agnostic therapeutic strategy for hexokinase 1-null/hexokinase 2-positive cancers. Cancer Res. 2019;79:5907–14. https://doi.org/10.1158/0008-5472.CAN-19-1789.CrossRefPubMed

42.

Zhang T, Zhu X, Wu H, Jiang K, Zhao G, Shaukat A, Deng G, Qiu C. Targeting the ROS/PI3K/AKT/HIF-1alpha/HK2 axis of breast cancer cells: combined administration of Polydatin and 2-Deoxy-d-glucose. J Cell Mol Med. 2019;23:3711–23. https://doi.org/10.1111/jcmm.14276.CrossRefPubMedPubMedCentral

43.

Liu R, Li Y, Tian L, Shi H, Wang J, Liang Y, Sun B, Wang S, Zhou M, Wu L, Nie J, Lin B, Tang S, et al. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating beta-catenin/c-Myc signaling in human hepatocellular carcinoma. Cancer Lett. 2019;443:34–46. https://doi.org/10.1016/j.canlet.2018.11.030.CrossRefPubMed

44.

Hanlon MM, Rakovich T, Cunningham CC, Ansboro S, Veale DJ, Fearon U, McGarry T. STAT3 mediates the differential effects of Oncostatin M and TNFalpha on RA synovial fibroblast and endothelial cell function. Front Immunol. 2019;10:2056. https://doi.org/10.3389/fimmu.2019.02056.CrossRefPubMedPubMedCentral

45.

Li W, Qiu Y, Hao J, Zhao C, Deng X, Shu G. Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: role of repressing glycolysis via miR-199a:HK2/PKM2 modulation. Food Chem Toxicol. 2018;121:156–65. https://doi.org/10.1016/j.fct.2018.08.030.CrossRefPubMed

46.

Ludvik AE, Pusec CM, Priyadarshini M, Angueira AR, Guo C, Lo A, Hershenhouse KS, Yang GY, Ding X, Reddy TE, Lowe WL Jr, Layden BT. HKDC1 is a novel hexokinase involved in whole-body glucose use. Endocrinology. 2016;157:3452–61. https://doi.org/10.1210/en.2016-1288.CrossRefPubMedPubMedCentral

47.

Zhang Z, Huang S, Wang H, Wu J, Chen D, Peng B, Zhou Q. High expression of hexokinase domain containing 1 is associated with poor prognosis and aggressive phenotype in hepatocarcinoma. Biochem Biophys Res Commun. 2016;474:673–9. https://doi.org/10.1016/j.bbrc.2016.05.007.CrossRefPubMed

48.

Kanai S, Shimada T, Narita T, Okabayashi K. Phosphofructokinase-1 subunit composition and activity in the skeletal muscle, liver, and brain of dogs. J Vet Med Sci. 2019;81:712–6. https://doi.org/10.1292/jvms.19-0049.CrossRefPubMedPubMedCentral

49.

Al Hasawi N, Alkandari MF, Luqmani YA. Phosphofructokinase: a mediator of glycolytic flux in cancer progression. Crit Rev Oncol Hematol. 2014;92:312–21. https://doi.org/10.1016/j.critrevonc.2014.05.007.CrossRefPubMed

50.

Zancan P, Almeida FV, Faber-Barata J, Dellias JM, Sola-Penna M. Fructose-2,6-bisphosphate counteracts guanidinium chloride-, thermal-, and ATP-induced dissociation of skeletal muscle key glycolytic enzyme 6-phosphofructo-1-kinase: a structural mechanism for PFK allosteric regulation. Arch Biochem Biophys. 2007;467:275–82. https://doi.org/10.1016/j.abb.2007.08.032.CrossRefPubMed

51.

Bartrons R, Rodriguez-Garcia A, Simon-Molas H, Castano E, Manzano A, Navarro-Sabate A. The potential utility of PFKFB3 as a therapeutic target. Expert Opin Ther Targets. 2018;22:659–74. https://doi.org/10.1080/14728222.2018.1498082.CrossRefPubMed

52.

Wu Z, Wu J, Zhao Q, Fu S, Jin J. Emerging roles of aerobic glycolysis in breast cancer. Clin Transl Oncol. 2019. https://doi.org/10.1007/s12094-019-02187-8.

53.

Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol. 2009;86:174–9. https://doi.org/10.1016/j.yexmp.2009.01.003.CrossRefPubMed

54.

Li S, Dai W, Mo W, Li J, Feng J, Wu L, Liu T, Yu Q, Xu S, Wang W, Lu X, Zhang Q, Chen K, et al. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma. Int J Cancer. 2017;141:2571–84. https://doi.org/10.1002/ijc.31022.CrossRefPubMed

55.

Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O'Neal J, Klarer AC, Clem AL, Telang S, Chesney J. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis. 2014;5:e1337. https://doi.org/10.1038/cddis.2014.292.CrossRefPubMedPubMedCentral

56.

Peng F, Li Q, Sun JY, Luo Y, Chen M, Bao Y. PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis. Int J Oncol. 2018;52:945–54. https://doi.org/10.3892/ijo.2018.4257.CrossRefPubMed

57.

Minchenko OH, Tsuchihara K, Minchenko DO, Bikfalvi A, Esumi H. Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells. World J Gastroenterol. 2014;20:13705–17. https://doi.org/10.3748/wjg.v20.i38.13705.CrossRefPubMedPubMedCentral

58.

Bobarykina AY, Minchenko DO, Opentanova IL, Moenner M, Caro J, Esumi H, Minchenko OH. Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. Acta Biochim Pol. 2006;53:789–99.CrossRefPubMed

59.

Han J, Meng Q, Xi Q, Wang H, Wu G. PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells. Cancer Biomark. 2017;18:249–56. https://doi.org/10.3233/CBM-160143.CrossRefPubMed

60.

van Niekerk G, Engelbrecht AM. Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target. Cell Oncol (Dordr). 2018;41:343–51. https://doi.org/10.1007/s13402-018-0383-7.CrossRef

61.

Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8:839–47. https://doi.org/10.1038/nchembio.1060.CrossRefPubMedPubMedCentral

62.

Azoitei N, Becher A, Steinestel K, Rouhi A, Diepold K, Genze F, Simmet T, Seufferlein T. PKM2 promotes tumor angiogenesis by regulating HIF-1alpha through NF-kappaB activation. Mol Cancer. 2016;15:3. https://doi.org/10.1186/s12943-015-0490-2.CrossRefPubMedPubMedCentral

63.

Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Semenza GL. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145:732–44. https://doi.org/10.1016/j.cell.2011.03.054.CrossRefPubMedPubMedCentral

64.

Park SH, Ozden O, Liu G, Song HY, Zhu Y, Yan Y, Zou X, Kang HJ, Jiang H, Principe DR, Cha YI, Roh M, Vassilopoulos A, et al. SIRT2-mediated Deacetylation and Tetramerization of pyruvate kinase directs glycolysis and tumor growth. Cancer Res. 2016;76:3802–12. https://doi.org/10.1158/0008-5472.CAN-15-2498.CrossRefPubMedPubMedCentral

65.

Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, Jiang Y, Zhou X, Li TT, Guan KL, Lei QY, Xiong Y. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell. 2013;52:340–52. https://doi.org/10.1016/j.molcel.2013.09.004.CrossRefPubMedPubMedCentral

66.

Nakatsu D, Horiuchi Y, Kano F, Noguchi Y, Sugawara T, Takamoto I, Kubota N, Kadowaki T, Murata M. L-cysteine reversibly inhibits glucose-induced biphasic insulin secretion and ATP production by inactivating PKM2. Proc Natl Acad Sci U S A. 2015;112:E1067–76. https://doi.org/10.1073/pnas.1417197112.CrossRefPubMedPubMedCentral

67.

Lo AK, Dawson CW, Young LS, Ko CW, Hau PM, Lo KW. Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells. J Pathol. 2015;237:238–48. https://doi.org/10.1002/path.4575.CrossRefPubMed

68.

Iansante V, Choy PM, Fung SW, Liu Y, Chai JG, Dyson J, Del Rio A, D’Santos C, Williams R, Chokshi S, Anders RA, Bubici C, Papa S. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun. 2015;6:7882. https://doi.org/10.1038/ncomms8882.CrossRefPubMedPubMedCentral

69.

Presek P, Reinacher M, Eigenbrodt E. Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett. 1988;242:194–8. https://doi.org/10.1016/0014-5793(88)81014-7.CrossRefPubMed

70.

Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A. 2010;107:1894–9. https://doi.org/10.1073/pnas.0914845107.CrossRefPubMedPubMedCentral

71.

Panasyuk G, Espeillac C, Chauvin C, Pradelli LA, Horie Y, Suzuki A, Annicotte JS, Fajas L, Foretz M, Verdeguer F, Pontoglio M, Ferre P, Scoazec JY, et al. PPARgamma contributes to PKM2 and HK2 expression in fatty liver. Nat Commun. 2012;3:672. https://doi.org/10.1038/ncomms1667.CrossRefPubMed

72.

Li YH, Li XF, Liu JT, Wang H, Fan LL, Li J, Sun GP. PKM2, a potential target for regulating cancer. Gene. 2018;668:48–53. https://doi.org/10.1016/j.gene.2018.05.038.CrossRefPubMed

73.

Wong N, Ojo D, Yan J, Tang D. PKM2 contributes to cancer metabolism. Cancer Lett. 2015;356:184–91. https://doi.org/10.1016/j.canlet.2014.01.031.CrossRefPubMed

74.

Wong CC, Au SL, Tse AP, Xu IM, Lai RK, Chiu DK, Wei LL, Fan DN, Tsang FH, Lo RC, Wong CM, Ng IO. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis. PLoS One. 2014;9:e115036. https://doi.org/10.1371/journal.pone.0115036.CrossRefPubMedPubMedCentral

75.

Feng J, Wu L, Ji J, Chen K, Yu Q, Zhang J, Chen J, Mao Y, Wang F, Dai W, Xu L, Wu J, Guo C. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:204. https://doi.org/10.1186/s13046-019-1194-z.CrossRefPubMedPubMedCentral

76.

Liu B, Jin J, Zhang Z, Zuo L, Jiang M, Xie C. Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1alpha signaling pathway. Biochem Cell Biol. 2019;97:397–405. https://doi.org/10.1139/bcb-2018-0310.CrossRefPubMed

77.

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33. https://doi.org/10.1126/science.1160809.CrossRefPubMedPubMedCentral

78.

Ganapathy-Kanniappan S. Molecular intricacies of aerobic glycolysis in cancer: current insights into the classic metabolic phenotype. Crit Rev Biochem Mol Biol. 2018;53:667–82. https://doi.org/10.1080/10409238.2018.1556578.CrossRefPubMed

79.

Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011;43:969–80. https://doi.org/10.1016/j.biocel.2010.02.005.CrossRefPubMed

80.

Serganova I, Cohen IJ, Vemuri K, Shindo M, Maeda M, Mane M, Moroz E, Khanin R, Satagopan J, Koutcher JA, Blasberg R. LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response. PLoS One. 2018;13:e0203965. https://doi.org/10.1371/journal.pone.0203965.CrossRefPubMedPubMedCentral

81.

Li Y, Lu Z, Liang Z, Ji D, Zhang P, Liu Q, Zheng X, Yao Y. Metastasis-associated in colon cancer-1 is associated with poor prognosis in hepatocellular carcinoma, partly by promoting proliferation through enhanced glucose metabolism. Mol Med Rep. 2015;12:426–34. https://doi.org/10.3892/mmr.2015.3416.CrossRefPubMed

82.

Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9. https://doi.org/10.1038/nrc1478.CrossRefPubMed

83.

Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene. 1999;18:3199–204. https://doi.org/10.1038/sj.onc.1202660.CrossRefPubMed

84.

Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol. 2001;69:522–30.PubMed

85.

Shang F, Liu M, Li B, Zhang X, Sheng Y, Liu S, Han J, Li H, Xiu R. The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells. Cancer Chemother Pharmacol. 2016;77:1087–96. https://doi.org/10.1007/s00280-016-3030-x.CrossRefPubMed

86.

Liu Y, Bi T, Shen G, Li Z, Wu G, Wang Z, Qian L, Gao Q. Lupeol induces apoptosis and inhibits invasion in gallbladder carcinoma GBC-SD cells by suppression of EGFR/MMP-9 signaling pathway. Cytotechnology. 2016;68:123–33. https://doi.org/10.1007/s10616-014-9763-7.CrossRefPubMed

87.

Shi Q, Le X, Wang B, Abbruzzese JL, Xiong Q, He Y, Xie K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene. 2001;20:3751–6. https://doi.org/10.1038/sj.onc.1204500.CrossRefPubMed

88.

Jung SY, Song HS, Park SY, Chung SH, Kim YJ. Pyruvate promotes tumor angiogenesis through HIF-1-dependent PAI-1 expression. Int J Oncol. 2011;38:571–6. https://doi.org/10.3892/ijo.2010.859.CrossRefPubMed

89.

Graziano F, Ruzzo A, Giacomini E, Ricciardi T, Aprile G, Loupakis F, Lorenzini P, Ongaro E, Zoratto F, Catalano V, Sarti D, Rulli E, Cremolini C, et al. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Pharmacogenomics J. 2017;17:258–64. https://doi.org/10.1038/tpj.2016.13.CrossRefPubMed

90.

Feng J, Dai W, Mao Y, Wu L, Li J, Chen K, Yu Q, Kong R, Li S, Zhang J, Ji J, Wu J, Mo W, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1alpha/PPAR-gamma/PKM2-mediated glycolysis. J Exp Clin Cancer Res. 2020;39:24. https://doi.org/10.1186/s13046-020-1528-x.CrossRefPubMedPubMedCentral

91.

Wang L, Yang Q, Peng S, Liu X. The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells. Onco Targets Ther. 2019;12:5359–73. https://doi.org/10.2147/OTT.S212465.CrossRefPubMedPubMedCentral

92.

Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2002;277:7610–8. https://doi.org/10.1074/jbc.M109950200.CrossRefPubMed

93.

Min JW, Kim KI, Kim HA, Kim EK, Noh WC, Jeon HB, Cho DH, Oh JS, Park IC, Hwang SG, Kim JS. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells. Biochem Biophys Res Commun. 2013;440:137–42. https://doi.org/10.1016/j.bbrc.2013.09.041.CrossRefPubMed

94.

Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, Liu SH, Cheng AL. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer. 2013;108:72–81. https://doi.org/10.1038/bjc.2012.559.CrossRefPubMed

95.

Morita M, Sato T, Nomura M, Sakamoto Y, Inoue Y, Tanaka R, Ito S, Kurosawa K, Yamaguchi K, Sugiura Y, Takizaki H, Yamashita Y, Katakura R, et al. PKM1 confers metabolic advantages and promotes cell-autonomous tumor cell growth. Cancer Cell. 2018;33:355–67 e7. https://doi.org/10.1016/j.ccell.2018.02.004.CrossRefPubMed

96.

Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62:3387–94.PubMed

97.

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812–9. https://doi.org/10.1182/blood-2006-07-035972.CrossRefPubMed

98.

Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R, Asara JM, Fitzpatrick J, Dillin A, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011;331:456–61. https://doi.org/10.1126/science.1196371.CrossRefPubMed

99.

Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, Kemp BE, Sakamoto K, Steinberg GR, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012;336:918–22. https://doi.org/10.1126/science.1215327.CrossRefPubMedPubMedCentral

100.

Hurley RL, Barre LK, Wood SD, Anderson KA, Kemp BE, Means AR, Witters LA. Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem. 2006;281:36662–72. https://doi.org/10.1074/jbc.M606676200.CrossRefPubMed

101.

Dagon Y, Hur E, Zheng B, Wellenstein K, Cantley LC, Kahn BB. p70S6 kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake. Cell Metab. 2012;16:104–12. https://doi.org/10.1016/j.cmet.2012.05.010.CrossRefPubMedPubMedCentral

102.

Fang G, Zhang P, Liu J, Zhang X, Zhu X, Li R, Wang H. Inhibition of GSK-3beta activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling. Cancer Lett. 2019;463:11–26. https://doi.org/10.1016/j.canlet.2019.08.003.CrossRefPubMed

103.

Cheng J, Zhang T, Ji H, Tao K, Guo J, Wei W. Functional characterization of AMP-activated protein kinase signaling in tumorigenesis. Biochim Biophys Acta. 1866;2016:232–51. https://doi.org/10.1016/j.bbcan.2016.09.006.CrossRef

104.

Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013;17:113–24. https://doi.org/10.1016/j.cmet.2012.12.001.CrossRefPubMed

105.

Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111. https://doi.org/10.1186/s13046-015-0221-y.CrossRefPubMedPubMedCentral

106.

Ren Y, Shen HM. Critical role of AMPK in redox regulation under glucose starvation. Redox Biol. 2019;25:101154. https://doi.org/10.1016/j.redox.2019.101154.CrossRefPubMedPubMedCentral

107.

Gao L, Lv G, Li R, Liu WT, Zong C, Ye F, Li XY, Yang X, Jiang JH, Hou XJ, Jing YY, Han ZP, Wei LX. Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation. Cancer Lett. 2019;454:215–23. https://doi.org/10.1016/j.canlet.2019.04.009.CrossRefPubMed

108.

Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes. 2013;62:2164–72. https://doi.org/10.2337/db13-0368.CrossRefPubMedPubMedCentral

109.

Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251–62. https://doi.org/10.1038/nrm3311.CrossRefPubMedPubMedCentral

110.

Domenech E, Maestre C, Esteban-Martinez L, Partida D, Pascual R, Fernandez-Miranda G, Seco E, Campos-Olivas R, Perez M, Megias D, Allen K, Lopez M, Saha AK, et al. AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol. 2015;17:1304–16. https://doi.org/10.1038/ncb3231.CrossRefPubMed

111.

Yoshida GJ. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol. 2017;10:67. https://doi.org/10.1186/s13045-017-0436-9.CrossRefPubMedPubMedCentral

112.

Huang F, Wang BR, Wang YG. Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma. World J Gastroenterol. 2018;24:4643–51. https://doi.org/10.3748/wjg.v24.i41.4643.CrossRefPubMedPubMedCentral

113.

Lee YJ, Jang BK. The role of autophagy in hepatocellular carcinoma. Int J Mol Sci. 2015;16:26629–43. https://doi.org/10.3390/ijms161125984.CrossRefPubMedPubMedCentral

114.

Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809–20. https://doi.org/10.1172/JCI20039.CrossRefPubMedPubMedCentral

115.

Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132–41. https://doi.org/10.1038/ncb2152.CrossRefPubMedPubMedCentral

116.

Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23. https://doi.org/10.1186/s13046-016-0303-5.CrossRefPubMedPubMedCentral

117.

Moldogazieva NT, Mokhosoev IM, Terentiev AA. Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK. Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12040862.

118.

Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140–56. https://doi.org/10.1038/nrd4204.CrossRefPubMedPubMedCentral

119.

Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14:381–95. https://doi.org/10.1016/s0898-6568(01)00271-6.CrossRefPubMed

120.

Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515–24. https://doi.org/10.1007/s10555-016-9637-x.CrossRefPubMed

121.

Fu X, Liu M, Qu S, Ma J, Zhang Y, Shi T, Wen H, Yang Y, Wang S, Wang J, Nan K, Yao Y, Tian T. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 2018;37:52. https://doi.org/10.1186/s13046-018-0677-7.CrossRefPubMedPubMedCentral

122.

Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614–22. https://doi.org/10.1038/aps.2017.5.CrossRefPubMedPubMedCentral

123.

Zhang H, Wang Q, Liu J, Cao H. Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma. Oncol Lett. 2018;15:9377–84. https://doi.org/10.3892/ol.2018.8536.CrossRefPubMedPubMedCentral

124.

Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC, Bentrem DJ. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008;37:426–31. https://doi.org/10.1097/MPA.0b013e3181735ccb.CrossRefPubMed

125.

Garrido P, Moran J, Alonso A, Gonzalez S, Gonzalez C. 17beta-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. Endocrinology. 2013;154:1979–89. https://doi.org/10.1210/en.2012-1558.CrossRefPubMed

126.

Samih N, Hovsepian S, Aouani A, Lombardo D, Fayet G. Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol 3-kinase and N-glycosylation. Endocrinology. 2000;141:4146–55. https://doi.org/10.1210/endo.141.11.7793.CrossRefPubMed

127.

Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–9. https://doi.org/10.1158/0008-5472.CAN-03-2904.CrossRefPubMed

128.

Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 2006;25:4683–96. https://doi.org/10.1038/sj.onc.1209595.CrossRefPubMed

129.

Grahame HD. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med. 2014;276:543–59. https://doi.org/10.1111/joim.12268.CrossRef

130.

Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447–54. https://doi.org/10.1128/mcb.12.12.5447.CrossRefPubMedPubMedCentral

131.

Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–32. https://doi.org/10.1038/nrc1187.CrossRefPubMed

132.

Huang LE. Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. Cell Death Differ. 2008;15:672–7. https://doi.org/10.1038/sj.cdd.4402302.CrossRefPubMed

133.

Yao J, Man S, Dong H, Yang L, Ma L, Gao W. Combinatorial treatment of Rhizoma Paridis saponins and sorafenib overcomes the intolerance of sorafenib. J Steroid Biochem Mol Biol. 2018;183:159–66. https://doi.org/10.1016/j.jsbmb.2018.06.010.CrossRefPubMed

134.

Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009;9:1084–101. https://doi.org/10.2174/138955709788922610.CrossRefPubMed

135.

Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177–85. https://doi.org/10.1016/j.cmet.2006.02.002.CrossRefPubMed

136.

DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20. https://doi.org/10.1016/j.cmet.2007.10.002.CrossRefPubMed

137.

Yoshida GJ. Emerging roles of Myc in stem cell biology and novel tumor therapies. J Exp Clin Cancer Res. 2018;37:173. https://doi.org/10.1186/s13046-018-0835-y.CrossRefPubMedPubMedCentral

138.

Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol. 2010;2:16–20. https://doi.org/10.4254/wjh.v2.i1.16.CrossRefPubMedPubMedCentral

139.

Mendez-Lucas A, Li X, Hu J, Che L, Song X, Jia J, Wang J, Xie C, Driscoll PC, Tschaharganeh DF, Calvisi DF, Yuneva M, Chen X. Glucose catabolism in liver tumors induced by c-MYC can be sustained by various PKM1/PKM2 ratios and pyruvate kinase activities. Cancer Res. 2017;77:4355–64. https://doi.org/10.1158/0008-5472.CAN-17-0498.CrossRefPubMedPubMedCentral

140.

Gruning NM, Lehrach H, Ralser M. Regulatory crosstalk of the metabolic network. Trends Biochem Sci. 2010;35:220–7. https://doi.org/10.1016/j.tibs.2009.12.001.CrossRefPubMed

141.

Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer. 2008;8:51–6. https://doi.org/10.1038/nrc2274.CrossRefPubMed

142.

Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, Aldape K, Cantley LC, Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol. 2012;14:1295–304. https://doi.org/10.1038/ncb2629.CrossRefPubMedPubMedCentral

143.

Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27:7381–93. https://doi.org/10.1128/MCB.00440-07.CrossRefPubMedPubMedCentral

144.

Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15:6479–83. https://doi.org/10.1158/1078-0432.CCR-09-0889.CrossRefPubMedPubMedCentral

145.

Lin CP, Liu JD, Chow JM, Liu CR, Liu HE. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anti-Cancer Drugs. 2007;18:161–70. https://doi.org/10.1097/CAD.0b013e3280109424.CrossRefPubMed

146.

Yao YX, Xu BH, Zhang Y. CX-3543 promotes cell apoptosis through Downregulation of CCAT1 in Colon Cancer cells. Biomed Res Int. 2018;2018:9701957. https://doi.org/10.1155/2018/9701957.CrossRefPubMedPubMedCentral

147.

Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74. https://doi.org/10.1038/nrg3074.CrossRefPubMed

148.

Liu W, Kang L, Han J, Wang Y, Shen C, Yan Z, Tai Y, Zhao C. miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect. Onco Targets Ther. 2018;11:1643–53. https://doi.org/10.2147/OTT.S161586.CrossRefPubMedPubMedCentral

149.

Ren L, Yao Y, Wang Y, Wang S. MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R. Biosci Rep. 2019;39. https://doi.org/10.1042/BSR20182442.

150.

Hu Y, Yang Z, Bao D, Ni JS, Lou J. miR-455-5p suppresses hepatocellular carcinoma cell growth and invasion via IGF-1R/AKT/GLUT1 pathway by targeting IGF-1R. Pathol Res Pract. 2019;215:152674. https://doi.org/10.1016/j.prp.2019.152674.CrossRefPubMed

151.

Wei S, Fan Q, Yang L, Zhang X, Ma Y, Zong Z, Hua X, Su D, Sun H, Li H, Liu Z. Promotion of glycolysis by HOTAIR through GLUT1 upregulation via mTOR signaling. Oncol Rep. 2017;38:1902–8. https://doi.org/10.3892/or.2017.5840.CrossRefPubMed

152.

Hua S, Lei L, Deng L, Weng X, Liu C, Qi X, Wang S, Zhang D, Zou X, Cao C, Liu L, Wu D. miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1. Oncogene. 2018;37:1624–36. https://doi.org/10.1038/s41388-017-0057-3.CrossRefPubMed

153.

Kim HR, Roe JS, Lee JE, Cho EJ, Youn HD. p53 regulates glucose metabolism by miR-34a. Biochem Biophys Res Commun. 2013;437:225–31. https://doi.org/10.1016/j.bbrc.2013.06.043.CrossRefPubMed

154.

Jiang JX, Gao S, Pan YZ, Yu C, Sun CY. Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. Mol Med Rep. 2014;10:995–1002. https://doi.org/10.3892/mmr.2014.2271.CrossRefPubMed

155.

Li W, Hao J, Zhang L, Cheng Z, Deng X, Shu G. Astragalin reduces hexokinase 2 through increasing miR-125b to inhibit the proliferation of hepatocellular carcinoma cells in vitro and in vivo. J Agric Food Chem. 2017;65:5961–72. https://doi.org/10.1021/acs.jafc.7b02120.CrossRefPubMed

156.

Lin YH, Wu MH, Huang YH, Yeh CT, Cheng ML, Chi HC, Tsai CY, Chung IH, Chen CY, Lin KH. Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. Hepatology. 2018;67:188–203. https://doi.org/10.1002/hep.29462.CrossRefPubMed

157.

Guo W, Qiu Z, Wang Z, Wang Q, Tan N, Chen T, Chen Z, Huang S, Gu J, Li J, Yao M, Zhao Y, He X. MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. Hepatology. 2015;62:1132–44. https://doi.org/10.1002/hep.27929.CrossRefPubMed

158.

Zhang LF, Lou JT, Lu MH, Gao C, Zhao S, Li B, Liang S, Li Y, Li D, Liu MF. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma. EMBO J. 2015;34:2671–85. https://doi.org/10.15252/embj.201591803.CrossRefPubMedPubMedCentral

159.

Xu F, Yan JJ, Gan Y, Chang Y, Wang HL, He XX, Zhao Q. miR-885-5p negatively regulates Warburg effect by silencing hexokinase 2 in liver Cancer. Mol Ther Nucleic Acids. 2019;18:308–19. https://doi.org/10.1016/j.omtn.2019.09.002.CrossRefPubMedPubMedCentral

160.

Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013;58:182–91. https://doi.org/10.1002/hep.26310.CrossRefPubMed

161.

Xu Q, Zhang M, Tu J, Pang L, Cai W, Liu X. MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma. Oncol Rep. 2015;34:2054–64. https://doi.org/10.3892/or.2015.4175.CrossRefPubMed

162.

Li Q, Pan X, Zhu D, Deng Z, Jiang R, Wang X. Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma through the miR-338-3p/PKM2 Axis under hypoxic stress. Hepatology. 2019;70:1298–316. https://doi.org/10.1002/hep.30671.CrossRefPubMed

163.

Zheng YL, Li L, Jia YX, Zhang BZ, Li JC, Zhu YH, Li MQ, He JZ, Zeng TT, Ban XJ, Yuan YF, Li Y, Guan XY. LINC01554-mediated glucose metabolism reprogramming suppresses Tumorigenicity in hepatocellular carcinoma via Downregulating PKM2 expression and inhibiting Akt/mTOR signaling pathway. Theranostics. 2019;9:796–810. https://doi.org/10.7150/thno.28992.CrossRefPubMedPubMedCentral

164.

Xu Q, Dou C, Liu X, Yang L, Ni C, Wang J, Guo Y, Yang W, Tong X, Huang D. Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis. Biomed Pharmacother. 2018;107:1692–704. https://doi.org/10.1016/j.biopha.2018.07.071.CrossRefPubMed

165.

Zhang M, Zhang H, Hong H, Zhang Z. MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway. Am J Cancer Res. 2019;9:765–78.PubMedPubMedCentral

166.

Hua S, Liu C, Liu L, Wu D. miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA. Biochem Biophys Res Commun. 2018;496:947–54. https://doi.org/10.1016/j.bbrc.2018.01.112.CrossRefPubMed

167.

Li X, Lu P, Li B, Yang R, Chu Y, Zhang Z, Wan H, Niu C, Wang C, Luo K. Sensitization of hepatocellular carcinoma cells to irradiation by miR34a through targeting lactate dehydrogenaseA. Mol Med Rep. 2016;13:3661–7. https://doi.org/10.3892/mmr.2016.4974.CrossRefPubMed

168.

Zhang HF, Wang YC, Han YD. MicroRNA34a inhibits liver cancer cell growth by reprogramming glucose metabolism. Mol Med Rep. 2018;17:4483–9. https://doi.org/10.3892/mmr.2018.8399.CrossRefPubMedPubMedCentral

169.

Li B, He L, Zuo D, He W, Wang Y, Zhang Y, Liu W, Yuan Y. Mutual regulation of MiR-199a-5p and HIF-1alpha modulates the Warburg effect in hepatocellular carcinoma. J Cancer. 2017;8:940–9. https://doi.org/10.7150/jca.17496.CrossRefPubMedPubMedCentral

170.

Chen Z, Zuo X, Zhang Y, Han G, Zhang L, Wu J, Wang X. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1alpha-mediated Warburg effect. Cell Death Dis. 2018;9:549. https://doi.org/10.1038/s41419-018-0616-8.CrossRefPubMedPubMedCentral

171.

Tang H, Li RP, Liang P, Zhou YL, Wang GW. miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol Lett. 2015;10:681–6. https://doi.org/10.3892/ol.2015.3264.CrossRefPubMedPubMedCentral

172.

Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology. 2012;55:1852–62. https://doi.org/10.1002/hep.25576.CrossRefPubMed

173.

Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV. C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–5. https://doi.org/10.1038/nature07823.CrossRefPubMedPubMedCentral

174.

Han H, Li W, Shen H, Zhang J, Zhu Y, Li Y. microRNA-129-5p, a c-Myc negative target, affects hepatocellular carcinoma progression by blocking the Warburg effect. J Mol Cell Biol. 2016;8:400–10. https://doi.org/10.1093/jmcb/mjw010.CrossRefPubMed

175.

Ren W, Wu S, Wu Y, Liu T, Zhao X, Li Y. MicroRNA-196a/−196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2. Cell Death Dis. 2019;10:333. https://doi.org/10.1038/s41419-019-1530-4.CrossRefPubMedPubMedCentral

176.

Li X, Zhao Q, Qi J, Wang W, Zhang D, Li Z, Qin C. lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARgamma pathway in hepatocellular carcinoma. Int J Oncol. 2018;53:551–66. https://doi.org/10.3892/ijo.2018.4418.CrossRefPubMedPubMedCentral

177.

Malakar P, Stein I, Saragovi A, Winkler R, Stern-Ginossar N, Berger M, Pikarsky E, Karni R. Long noncoding RNA MALAT1 regulates Cancer glucose metabolism by enhancing mTOR-mediated translation of TCF7L2. Cancer Res. 2019;79:2480–93. https://doi.org/10.1158/0008-5472.CAN-18-1432.CrossRefPubMed

178.

Reyes RK, Motiwala T, Jacob ST. Regulation of glucose metabolism in hepatocarcinogenesis by microRNAs. Gene Expr. 2014;16:85–92. https://doi.org/10.3727/105221614X13919976902093.CrossRefPubMedPubMedCentral

179.

Wang Z, Kang F, Gao Y, Liu Y, Xu X, Ma X, Ma W, Yang W, Wang J. Metformin promotes 2-Deoxy-2-[(18)F]Fluoro-D-glucose uptake in hepatocellular carcinoma cells through FoxO1-mediated Downregulation of Glucose-6-phosphatase. Mol Imaging Biol. 2018;20:388–97. https://doi.org/10.1007/s11307-017-1150-2.CrossRefPubMed

180.

Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Ishige N. 2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells. Oncol Lett. 2017;13:800–4. https://doi.org/10.3892/ol.2016.5510.CrossRefPubMed

181.

Takemura A, Che XF, Tabuchi T, Moriya S, Miyazawa K, Tomoda A. Enhancement of cytotoxic and pro-apoptotic effects of 2-aminophenoxazine-3-one on the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2, and the rat normal hepatocellular cell line RLN-10 in combination with 2-deoxy-D-glucose. Oncol Rep. 2012;27:347–55. https://doi.org/10.3892/or.2011.1531.CrossRefPubMed

182.

Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2004;4:449–57. https://doi.org/10.1586/14737140.4.3.449.CrossRefPubMed

183.

Telang S, Clem BF, Klarer AC, Clem AL, Trent JO, Bucala R, Chesney J. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation. J Transl Med. 2012;10:95. https://doi.org/10.1186/1479-5876-10-95.CrossRefPubMedPubMedCentral

184.

Wang Y, Hao F, Nan Y, Qu L, Na W, Jia C, Chen X. PKM2 inhibitor Shikonin overcomes the Cisplatin resistance in bladder Cancer by inducing Necroptosis. Int J Biol Sci. 2018;14:1883–91. https://doi.org/10.7150/ijbs.27854.CrossRefPubMedPubMedCentral

185.

Szokoloczi O, Schwab R, Petak I, Orfi L, Pap A, Eberle AN, Szuts T, Keril G. TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases. J Recept Signal Transduct Res. 2005;25:217–35. https://doi.org/10.1080/10799890500464621.CrossRefPubMed

186.

Liu T, Li S, Wu L, Yu Q, Li J, Feng J, Zhang J, Chen J, Zhou Y, Ji J, Chen K, Mao Y, Wang F, et al. Experimental study of hepatocellular carcinoma treatment by Shikonin through regulating PKM2. J Hepatocell Carcinoma. 2020;7:19–31. https://doi.org/10.2147/JHC.S237614.CrossRefPubMedPubMedCentral

187.

Dumenci OE, Abellona UM, Khan SA, Holmes E, Taylor-Robinson SD. Exploring metabolic consequences of CPS1 and CAD Dysregulation in hepatocellular carcinoma by network reconstruction. J Hepatocell Carcinoma. 2020;7:1–9. https://doi.org/10.2147/JHC.S239039.CrossRefPubMedPubMedCentral

188.

Li J, Guo C, Wu J. 15-Deoxy--(12,14)-prostaglandin J2 (15d-PGJ2), an endogenous ligand of PPAR-gamma: function and mechanism. PPAR Res. 2019;2019:7242030. https://doi.org/10.1155/2019/7242030.CrossRefPubMedPubMedCentral

189.

Wu L, Li J, Liu T, Li S, Feng J, Yu Q, Zhang J, Chen J, Zhou Y, Ji J, Chen K, Mao Y, Wang F, et al. Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway. Cancer Med. 2019;8:4806–20. https://doi.org/10.1002/cam4.2388.CrossRefPubMedPubMedCentral

190.

Wang W, Wu L, Li J, Ji J, Chen K, Yu Q, Li S, Feng J, Liu T, Zhang J, Chen J, Zhou Y, Mao Y, et al. Alleviation of hepatic ischemia reperfusion injury by Oleanolic acid pretreating via reducing HMGB1 release and inhibiting apoptosis and autophagy. Mediat Inflamm. 2019;2019:3240713. https://doi.org/10.1155/2019/3240713.CrossRef

191.

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1.CrossRefPubMed

192.

Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol. 2020;72:342–52. https://doi.org/10.1016/j.jhep.2019.09.010.CrossRefPubMed

193.

Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 2018;48:103–14. https://doi.org/10.1093/jjco/hyx180.CrossRefPubMed

194.

Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A. A randomized phase II open-label multi-institution study of the combination of Bevacizumab and Erlotinib compared to Sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma. Oncology. 2018;94:329–39. https://doi.org/10.1159/000485384.CrossRefPubMed

195.

von Felden J. New systemic agents for hepatocellular carcinoma: an update 2020. Curr Opin Gastroenterol. 2020;36:177–83. https://doi.org/10.1097/MOG.0000000000000626.CrossRef

196.

Itoh S, Yoshizumi T, Yugawa K, Imai D, Yoshiya S, Takeishi K, Toshima T, Harada N, Ikegami T, Soejima Y, Kohashi K, Oda Y, Mori M. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. 2020. https://doi.org/10.1002/hep.31206.

197.

Kudo M. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12051089.

198.

Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020. https://doi.org/10.2217/fon-2020-0162.

199.

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745.CrossRefPubMed

200.

Zhang H, Li XX, Yang Y, Zhang Y, Wang HY, Zheng XFS. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. Hepatology. 2018;67:2271–86. https://doi.org/10.1002/hep.29715.CrossRefPubMed

201.

Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology. 2009;50:1392–402. https://doi.org/10.1002/hep.23163.CrossRefPubMed

202.

Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S, Chang C. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008;135:947–55, 55 e1–5. https://doi.org/10.1053/j.gastro.2008.05.046.CrossRefPubMed

203.

Sun RF, Zhao CY, Chen S, Yu W, Zhou MM, Gao CR. Androgen receptor stimulates hexokinase 2 and induces glycolysis by PKA/CREB signaling in hepatocellular carcinoma. Dig Dis Sci. 2020. https://doi.org/10.1007/s10620-020-06229-y.

204.

Groupe d’Etude et de Traitement du Carcinome H. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology. 2004;40:1361–9. https://doi.org/10.1002/hep.20474.CrossRef

205.

Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology. 1995;21:1535–42.PubMed

206.

Xiao Y, Sun Y, Liu G, Zhao J, Gao Y, Yeh S, Gong L, Chang C. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype. Cancer Lett. 2019;444:175–87. https://doi.org/10.1016/j.canlet.2018.11.004.CrossRefPubMed

207.

Jiang X, Kanda T, Nakamoto S, Miyamura T, Wu S, Yokosuka O. Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. Exp Cell Res. 2014;323:326–36. https://doi.org/10.1016/j.yexcr.2014.02.017.CrossRefPubMed

208.

Kanda T, Takahashi K, Nakamura M, Nakamoto S, Wu S, Haga Y, Sasaki R, Jiang X, Yokosuka O. Androgen receptor could be a potential therapeutic target in patients with advanced hepatocellular carcinoma. Cancers (Basel). 2017;9. https://doi.org/10.3390/cancers9050043.

209.

Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: A case series report. Aging. 2009;1:988–1007. https://doi.org/10.18632/aging.100114.CrossRefPubMedPubMedCentral

210.

Goldstein I, Hager GL. Transcriptional and chromatin regulation during fasting - the genomic era. Trends Endocrinol Metab. 2015;26:699–710. https://doi.org/10.1016/j.tem.2015.09.005.CrossRefPubMedPubMedCentral

211.

Sukonina V, Ma H, Zhang W, Bartesaghi S, Subhash S, Heglind M, Foyn H, Betz MJ, Nilsson D, Lidell ME, Naumann J, Haufs-Brusberg S, Palmgren H, et al. FOXK1 and FOXK2 regulate aerobic glycolysis. Nature. 2019;566:279–83. https://doi.org/10.1038/s41586-019-0900-5.CrossRefPubMed

212.

Bianchi G, Martella R, Ravera S, Marini C, Capitanio S, Orengo A, Emionite L, Lavarello C, Amaro A, Petretto A, Pfeffer U, Sambuceti G, Pistoia V, et al. Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models. Oncotarget. 2015;6:11806–19. https://doi.org/10.18632/oncotarget.3688.CrossRefPubMedPubMedCentral

213.

Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schulte-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci U S A 1994; 91: 9995–9. doi: https://doi.org/10.1073/pnas.91.21.9995.

214.

Ito J, Uchida H, Yokote T, Ohtake K, Kobayashi J. Fasting-induced intestinal apoptosis is mediated by inducible nitric oxide synthase and interferon-{gamma} in rat. Am J Physiol Gastrointest Liver Physiol. 2010;298:G916–26. https://doi.org/10.1152/ajpgi.00429.2009.CrossRefPubMed

215.

Yoshida GJ. Emerging role of epithelial-mesenchymal transition in hepatic cancer. J Exp Clin Cancer Res. 2016;35:141. https://doi.org/10.1186/s13046-016-0419-7.CrossRefPubMedPubMedCentral

216.

Zhang Z, Li TE, Chen M, Xu D, Zhu Y, Hu BY, Lin ZF, Pan JJ, Wang X, Wu C, Zheng Y, Lu L, Jia HL, et al. MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming. Br J Cancer. 2020;122:209–20. https://doi.org/10.1038/s41416-019-0658-4.CrossRefPubMed

217.

Zhang Y, Zeng S, Ma J, Deng G, Qu Y, Guo C, Shen H. Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance. J Exp Clin Cancer Res. 2016;35:111. https://doi.org/10.1186/s13046-016-0387-y.CrossRefPubMedPubMedCentral

218.

Duran A, Hernandez ED, Reina-Campos M, Castilla EA, Subramaniam S, Raghunandan S, Roberts LR, Kisseleva T, Karin M, Diaz-Meco MT, Moscat J. p62/SQSTM1 by binding to vitamin D receptor inhibits hepatic stellate cell activity, fibrosis, and liver Cancer. Cancer Cell. 2016;30:595–609. https://doi.org/10.1016/j.ccell.2016.09.004.CrossRefPubMedPubMedCentral

219.

Yoshida GJ, Azuma A, Miura Y, Orimo A. Activated fibroblast program orchestrates tumor initiation and progression; molecular mechanisms and the associated therapeutic strategies. Int J Mol Sci. 2019;20. https://doi.org/10.3390/ijms20092256.

At a glance: The STEP trials

Springer Medicine

Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

OTUD7B suppresses Smac mimetic-induced lung cancer cell invasion and migration via deubiquitinating TRAF3

Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Dexosomes as a cell-free vaccine for cancer immunotherapy

Hsa_circ_0001944 promotes the growth and metastasis in bladder cancer cells by acting as a competitive endogenous RNA for miR-548

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer